Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2026 ASCO GU
2026 ASCO GI
SUO 2025
SABCS 2025
ASH 2025
Calendar
View All
Topics
AI in Oncology
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
2017 APOS Annual Conference,2017 APOS Annual Conference
«
1
»
Advertisement
Advertisement
Mar
16
Today In Oncology
Benmelstobart Plus Anlotinib in First-Line Treatment for PD-L1–Positive Advanced NSCLC
Optical Genome Mapping Detects Additional Genetic Variants in Nearly 20% of Individuals With Acute Leukemia
New Prostate Cancer Risk Classification With PSMA-PET
FDA Consolidates Systems Into One Cohesive Adverse Event Monitoring Tool
No Recurrence-Free Survival Benefit With Adjuvant Pembrolizumab in Hepatocellular Carcinoma
View More
Advertisement
